Letters to the EditorA Cerner Real-World Data Study of Spinal Muscular Atrophy Patients With Positive COVID-19 InfectionDigala, Lakshmi P. MBBS*; Prasanna, Shivika MS†; Rao, Praveen PhD†; Qureshi, Adnan I. MD*; Govindarajan, Raghav MD* Author Information *Department of Neurology, University of Missouri Health Care, Columbia, MO †Department of Health Management and Informatics, Department of Electrical Engineering and Computer Science, Center for Biomedical Informatics, University of Missouri, Columbia, MO The authors report no conflicts of interest. R. Govindarajan serves on the advisory board of Alexion Pharmaceuticals, Argenx Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst pharmaceuticals, Roche pharmaceuticals, Amicus pharmaceuticals, and Sarepta pharmaceuticals and has received research support from Alexion Pharmaceuticals, Ra Pharmaceuticals, Strongbridge Pharmaceuticals, American Academy of Neurology, AMARC Enterprises/Poly-MVA, Dysimmune Foundation, and InfuCare. He has received speaking honorarium from American Academy of Neurology, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst Pharmaceuticals, and Muscular Dystrophy Association and publication honorarium from Springer Publishing, United States, and royalties from CRC press. Ethical Publication Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Journal of Clinical Neuromuscular Disease: June 2021 - Volume 22 - Issue 4 - p 239-240 doi: 10.1097/CND.0000000000000360 Buy Metrics Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.